All In Biotech

Drug Trial Radar · NCT05879432

LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Mar 8, 2024

Primary completion

Mar 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Arch Biopartners Inc.Industry
Sponsor type
Industry
First posted
May 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.

Conditions

  • Acute Kidney Injury
  • Cardiac Surgery

Interventions

  • LSALT PeptideDrug

    LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH, binds to dipeptidase-1 (DPEP-1) but does not inhibit its biologic enzymatic activity, potentially minimizing off-target or other adverse effects. LSALT peptide inhibits leukocyte recruitment in multiple experimental disease models through the direct inhibition of leukocyte adhesion to DPEP-1 present in lungs, kidney, and liver.

  • PlaceboDrug

    0.9% saline solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteriaTime frame: 7 days

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary

    Calgary, Alberta, Canada · Recruiting

  • Royal Columbian Hospital

    New Westminster, British Columbia, Canada · Recruiting

  • Unity Health Toronto, St. Michael's Hospital

    Toronto, Ontario, Canada · Recruiting

  • University Health Network, Toronto General Hospital

    Toronto, Ontario, Canada · Recruiting

  • Gazi University

    Yenimahalle, Ankara, Turkey (Türkiye) · Completed

  • Kosuyolu High Specialization Training and Research Hospital

    Kartal, Istanbul, Turkey (Türkiye) · Completed

  • Erciyes University, Faculty of Medicine - Semiha Kibar Organ Transplant & Dialysis Hospital

    Melikgazi, Kayseri, Turkey (Türkiye) · Completed

  • Kocaeli University, Faculty of Medicine Practices and Research Hospital

    İzmit, Kocaeli, Turkey (Türkiye) · Completed

  • Sütçü İmam University, Faculty of Medicine

    Kahramanmaraş, Onikişubat, Turkey (Türkiye) · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.